Discoveries, drugs and skeletal disorders (original) (raw)

• Cummings, S. R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761–1767 (2002).
  Article PubMed Google Scholar
• Doherty, D. A., Sanders, K. M., Kotowicz, M. A. & Prince, R. L. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporosis Int. 12, 16–23 (2001).
  CAS Google Scholar
• Ray, N. F., Chan, J. K., Thamer, M. & Melton, L. J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12, 24–35 (1997).
  CAS PubMed Google Scholar
• Burr, D. B. The contribution of the organic matrix to bone's material properties. Bone 31, 8–11 (2002).
  CAS PubMed Google Scholar
• Kanis, J. A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929–1936 (2002).
  PubMed Google Scholar
• Hunziker, E. B. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 10, 432–463 (2002).
  CAS PubMed Google Scholar
• Klareskog, L., Lorentzen, J., Padyukov, L. & Alfredsson, L. Genes and environment in arthritis: can RA be prevented? Arthritis Res. 4 (Suppl. 3), S31–S36 (2002).
  PubMed PubMed Central Google Scholar
• Goltzman, D., Karaplis, A. C., Kremer, R. & Rabbani, S. A. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88 (Suppl. 12), 2903–2908 (2000).
  CAS PubMed Google Scholar
• Gemmell, E., Yamazaki, K. & Seymour, G. J. Destructive periodontitis lesions are determined by the nature of the lymphocytic response. Crit. Rev. Oral Biol. Med. 13, 17–34 (2002).
  CAS PubMed Google Scholar
• Reddy, S. V., Kurihara, N., Menaa, C. & Roodman, G. D. Paget's disease of bone: a disease of the osteoclast. Rev. Endocr. Metab. Disord. 2, 195–201 (2001).
  CAS PubMed Google Scholar
• Econs, M. J. New insights into the pathogenesis of inherited phosphate wasting disorders. Bone 25, 131–135 (1999).
  CAS PubMed Google Scholar
• White, K. E. et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nature Genet. 26, 345–348 (2000).The initial description of the discovery of FGF23 in a syndrome of hypophosphataemic rickets.
  CAS Google Scholar
• Mawer, E. B. & Davies, M. Vitamin D nutrition and bone disease in adults. Rev. Endocr. Metab. Disord. 2, 175–186 (2001).
  Google Scholar
• Aubin, J. E. Regulation of osteoblast formation and function. Rev. Endocr. Metab. Disord. 2, 81–94 (2001).
  CAS PubMed Google Scholar
• Komori, T. et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755–764 (1997).
  CAS PubMed Google Scholar
• Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002).
  CAS PubMed Google Scholar
• Sabatakos, G. et al. Overexpression of ΔFOSB transcription factor(s) increases bone formation and inhibits adipogenesis. Nature Med. 6, 985–990 (2000).
  CAS PubMed Google Scholar
• Jochum, W. et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nature Med. 6, 985–990 (2000).
  Google Scholar
• Rouleau, M. F., Mitchell, J. & Goltzman, D. In vivo distribution of parathyroid hormone receptor in bone: evidence that a predominant osseous target cell is not the mature osteoblast. Endocrinology 123, 187–191 (1988).
  CAS PubMed Google Scholar
• Suda, T., Kobayashi, K., Jimi, E., Udagawa, N. & Takahashi, N. The molecular basis of osteoclast differentiation and activation. Novartis Found. Symp. 232, 235–247 (2001).
  CAS PubMed Google Scholar
• Watanuki, M. et al. Role of inducible nitric oxide synthase in skeletal adaptation to acute increases in mechanical loading. J. Bone Miner. Res. 17, 1015–1025 (2002).
  CAS PubMed Google Scholar
• Miao, D., He, B., Karaplis, A. C. & Goltzman, D. Parathyroid hormone is essential for normal fetal bone formation. J. Clin. Invest. 109, 1173–1182 (2002).The first report of the physiological role of PTH as an anabolic agent in fetal bone.
  CAS PubMed PubMed Central Google Scholar
• Amizuka, N. et al. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev. Biol. 175, 166–176 (1996).
  CAS PubMed Google Scholar
• Miao, D. et al. Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 276, 32204–32213 (2001).
  CAS PubMed Google Scholar
• Carpio, L., Gladu, J., Goltzman, D. & Rabbani, S. A. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am. J. Physiol. Endocrinol. Metab. 281, E489–E499 (2001).
  CAS PubMed Google Scholar
• Jilka, R. L. et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104, 439–446 (1999).A description of the inhibition of apoptosis as an important mechanism for the anabolic effect of PTH.
  CAS PubMed PubMed Central Google Scholar
• Rodan, G. A. & Martin, T. J. Therapeutic approaches to bone diseases. Science 289, 1508–1514 (2000).
  CAS PubMed Google Scholar
• Dempster, D. W. et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16, 1846–1853 (2001).
  CAS PubMed Google Scholar
• Canalis, E. Novel treatments for osteoporosis. J. Clin. Invest. 106, 177–179 (2000).
  CAS PubMed PubMed Central Google Scholar
• Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–523 (2001).A ground-breaking report of the involvement of LRP5 in bone formation.
  CAS PubMed Google Scholar
• Little, C. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11–19 (2002).
  CAS PubMed Google Scholar
• Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513–1521 (2002).
  CAS PubMed Google Scholar
• Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157, 303–314 (2002).
  CAS PubMed PubMed Central Google Scholar
• Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signaling. Nature 417, 664–667 (2002).
  CAS PubMed Google Scholar
• Hunter, I., McGregor, D. & Robins, S. P. Caspase-dependent cleavage of cadherins and catenins during osteoblast apoptosis. J. Bone Miner. Res. 16, 466–477 (2001).
  CAS PubMed Google Scholar
• Marie, P. J. Role of N-cadherin in bone formation. J. Cell. Physiol. 190, 297–305 (2002).
  CAS PubMed Google Scholar
• Lecanda, F. et al. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J. Cell Biol. 151, 931–944 (2000).
  CAS PubMed PubMed Central Google Scholar
• Tanaka, Y. et al. H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts. J. Biol. Chem. 277, 21446–21452 (2002).
  CAS PubMed Google Scholar
• Bianco, P., Riminucci, M., Gronthos, S. & Robey, P. G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19, 180–192 (2001).
  CAS PubMed Google Scholar
• Nuttall, M. E. & Gimble, J. M. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 27, 177–184 (2000).
  CAS PubMed Google Scholar
• Capdevila, J. & Belmonte, J. C. Patterning mechanisms controlling vertebrate limb development. Annu. Rev. Cell Dev. Biol. 17, 87–132 (2001).
  CAS PubMed Google Scholar
• Garrett, I. R. & Mundy, G. R. The role of statins as potential targets for bone formation. Arthritis Res. 4, 237–240 (2002).
  PubMed PubMed Central Google Scholar
• Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504–1508 (2000).An excellent review of the molecular regulation of osteoclast function.
  CAS PubMed Google Scholar
• Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the _c_-Src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693–702 (1991).
  CAS PubMed Google Scholar
• Sanjay, A., et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, αvβ3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 152, 181–196 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hu, P. Y. et al. A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries. Hum. Mutat. 1, 288–292 (1992).
  CAS PubMed Google Scholar
• Teti, A. et al. Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J. Clin. Invest. 83, 227–233 (1989).
  CAS PubMed PubMed Central Google Scholar
• Blair, H. C., Teitelbaum, S. L., Ghiselli, R. & Gluck, S. Ostoeclastic bone resorption by a polarized vacuolar proton pump. Science 245, 855–857 (1989).
  CAS PubMed Google Scholar
• Stroup, G. B. et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16, 1747–1749 (2001).
  Google Scholar
• Tondravi, M. M. et al. Osteopetrosis in mice lacking hematopoietic transcription factor PU.1. Nature 386, 81–84 (1997).
  CAS PubMed Google Scholar
• Grigoriadis, A. E. et al. _c_-Fos: a key regulator of osteoclast–macrophage lineage determination and bone remodeling. Science 266, 443–448 (1994).
  CAS PubMed Google Scholar
• Iotsova, V. et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med. 3, 1285–1289 (1997).
  CAS PubMed Google Scholar
• Hodgkinson, C. A. et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic helix–loop–helix zipper protein. Cell 74, 395–404 (1993).
  CAS PubMed Google Scholar
• Theill, L. E., Boyle, W. J. & Penninger, J. M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20, 795–823 (2002).
  CAS PubMed Google Scholar
• Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).An initial description of the role of OPG in the regulation of bone density.
  CAS PubMed Google Scholar
• Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600–605 (2000).
  CAS PubMed Google Scholar
• Delmas, P. D. Treatment of postmenopausal osteoporosis. Lancet 359, 2018–2026 (2002).An excellent review of the current therapy for postmenopausal osteoporosis.
  CAS PubMed Google Scholar
• Russell, R. G. et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14 (Suppl. 2), 53–65 (1999).
  CAS PubMed Google Scholar
• Lehenkari, P. P. et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61, 1255–1262 (2002).
  CAS PubMed Google Scholar
• Lindsay, R, Hart, D. M. & Fogelman, I. Bone mass after withdrawal of oestrogen replacement. Lancet 1, 729 (1981).
• Manolagas, S. C., Kousteni, S. & Jilka, R. L. Sex steroids and bone. Recent Prog. Horm. Res. 57, 385–409 (2002).
  CAS PubMed Google Scholar
• Riggs, B. L., Khosla, S. & Melton, L. J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279–302 (2002).References 61 and 62 are both comprehensive reviews of the effect of sex steroids on bone.
  CAS PubMed Google Scholar
• Lufkin, E. G., Wong, M. & Deal, C. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum. Dis. Clin. North Am. 27, 163–185 (2001).
  CAS PubMed Google Scholar
• Martin, T. J. Calcitonin, an update. Bone 24 (Suppl. 5), 63S–65S (1999).
  CAS PubMed Google Scholar
• Nguyen, T. V. & Eisman, J. A. Genetics of fracture: challenges and opportunities. J. Bone Miner. Res. 15, 1243–1252 (2000).
  Google Scholar
• Karsenty, G. & Wagner, E. F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell. 2, 389–406 (2002).
  CAS PubMed Google Scholar
• Kim, H. J., Rice, D. P., Kettunen, P. J. & Thesleff, I. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125, 1241–1251 (1998).
  CAS PubMed Google Scholar
• Suda, N. et al. Parathyroid hormone-related protein is required for normal intramembranous bone development. J. Bone Miner. Res. 16, 2182–2191 (2001).
  CAS PubMed Google Scholar
• Zhang, X. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109, 1405–1415 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bi, W. et al. Sox9 is required for cartilage formation. Nature Genet. 22, 85–89 (1999).
  CAS PubMed Google Scholar
• Smits, P. et al. The transcription factors l-Sox5 and Sox6 are essential for cartilage formation. Dev. Cell 1, 277–290 (2001).
  CAS PubMed Google Scholar
• Panda, D. K. et al. The transcription factor SOX9 regulates cell cycle and differentiation genes in chondrocytic CFK2 cells. J. Biol. Chem. 276, 41229–41236 (2001).
  CAS PubMed Google Scholar
• Amizuka, N., Warshawsky, H., Henderson, J. E., Goltzman, D. & Karaplis, A. C. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126, 1611–1623 (1994).A demonstration of the crucial role of PTHrP in endochondral bone formation.
  CAS PubMed Google Scholar
• Chung, U. I., Schipani, E., McMahon, A. P. & Kronenberg, H. M. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. J. Clin. Invest. 107, 295–304 (2001).
  CAS PubMed PubMed Central Google Scholar
• Ornitz, D. M. & Marie, P. J. FGF signaling pathways in endochondral and intramembraneous bone development and human genetic disease. Genes Dev. 16, 1446–1465 (2002).
  CAS PubMed Google Scholar
• Zelzer, E. et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129, 1893–1904 (2002).
  CAS PubMed Google Scholar
• St-Jacques, B., Hammerschmidt, M. & McMahon, A. P. Indian hedgehog signalling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072–2086 (1999).
  CAS PubMed PubMed Central Google Scholar
• Takeda, S. & Karsenty, G. Central control of bone formation. J. Bone Miner. Metab. 19, 195–198 (2001).
  CAS PubMed Google Scholar
• Panda, D. K. et al. Targeted ablation of the 25-hydroxyvitamin D1 α-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl Acad. Sci. USA 98, 7498–7503 (2001).
  CAS PubMed PubMed Central Google Scholar
• Amling, M. et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140, 4982–4987 (1999).
  CAS PubMed Google Scholar
• Mosekilde, L. Mechanisms of age-related bone loss. Novartis Found. Symp. 235, 150–166 (2001).
  CAS PubMed Google Scholar
• Norman, T. L. & Wang, Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 20, 375–379 (1997).
  CAS PubMed Google Scholar
• Gazit, D., Zilberman, Y., Ebner, R. & Kahn, A. Bone loss (osteopenia) in old male mice results from diminished activity and availability of TGF-β. J. Cell. Biochem. 70, 478–488 (1998).
  CAS PubMed Google Scholar
• Aerssens, J., Boonen, S., Joly, J. & Dequeker, J. Variations in trabecular bone composition with anatomical site and age: potential implications for bone quality assessment. J. Endocrinol. 155, 411–421 (1997).
  CAS PubMed Google Scholar
• Seeman, E. Pathogenesis of bone fragility in women and men. Lancet 359, 1841–1850 (2002).
  PubMed Google Scholar
• Delmas, P. D. et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporosis Int. 13, 1–5 (2002).A description of the ethical dilemma in the use of placebo controls for treatment of osteoporosis.
  CAS Google Scholar
• The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276, 1389–1396 (1996).
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).A landmark report on the effects of combinations of oestrogen and progesterone on bone and on other organs in postmenopausal women.
• Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637–645 (1999).
  CAS PubMed Google Scholar
• Barrett-Connor, E. et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287, 847–857 (2002).
  CAS PubMed Google Scholar
• Watts, N. B. Treatment of osteoporosis with bisphosphonates. Rheum. Dis. Clin. North. Am. 27, 197–214 (2001).
  CAS PubMed Google Scholar
• Hosking, D. et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N. Engl. J. Med. 338, 485–492 (1998).
  CAS PubMed Google Scholar
• Mortensen, L. et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metab. 83, 396–402 (1998).
  CAS PubMed Google Scholar
• Schnitzer, T. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12, 1–12 (2000).
  CAS Google Scholar
• Cummings, S. R. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280, 2077–2082 (1998).
  CAS PubMed Google Scholar
• Harris, S. T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282, 1344–1352 (1999).
  CAS PubMed Google Scholar
• Black, D. M. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348, 1535–1541 (1996).
  CAS PubMed Google Scholar
• McClung, M. R. et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344, 333–340 (2001).
  CAS PubMed Google Scholar
• Ringe, J. D., Orwall, E., Daifotis, A. & Lombardi, A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporosis Int. 13, 195–199 (2002).
  CAS Google Scholar
• Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292–299 (1998).
  CAS PubMed Google Scholar
• Reid, I. R. et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346, 653–661 (2002).
  CAS PubMed Google Scholar
• Siris, E. S. Goals of treatment for Paget's disease of bone. J. Bone Miner. Res. 14 (Suppl. 2), 49–52 (1999).
  PubMed Google Scholar
• Coleman, R. E. Optimising treatment of bone metastases by Aredia and Zometa. Breast Cancer 7, 361–369 (2000).
  CAS PubMed Google Scholar
• Glorieux, F. H. et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339, 947–952 (1998).
  CAS PubMed Google Scholar
• Lehmann, H. J., Mouritzen, U., Christgau, S., Cloos, P. A. & Christiansen, C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann. Rheum. Dis. 61, 530–533 (2002).
  CAS PubMed PubMed Central Google Scholar
• Chesnut, C. H. et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109, 267–276 (2000).
  CAS PubMed Google Scholar
• Selye, H. On stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology 16, 547–558 (1932).
  CAS Google Scholar
• Reeve, J. et al. The anabolic effect of low doses of human parathyroid hormone fragment on the skeleton in postmenopausal osteoporosis. Lancet 1, 1035–1038 (1976).
  CAS PubMed Google Scholar
• Tam, C. S., Heersche, J. N., Murray, T. M. & Parsons, J. A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110, 506–512 (1982).
  CAS PubMed Google Scholar
• Dobnig, H. & Turner, R. T. The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138, 4607–4612 (1997).
  CAS PubMed Google Scholar
• Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).The first report of the beneficial effect of PTH treatment on fractures in postmenopausal osteoporosis.
  CAS PubMed Google Scholar
• Brown, A. J. Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis. 38 (Suppl. 5), S3–S19 (2001).
  CAS PubMed Google Scholar
• Dawson-Hughes, B., Harris, S. S., Krall, E. A. & Dallal, G. E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670–676 (1997).
  CAS PubMed Google Scholar
• Chapuy, M. C. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, 1637–1642 (1992).
  CAS PubMed Google Scholar
• Negro-Vilar, A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 84, 3459–3462 (1999).
  CAS PubMed Google Scholar
• Lieberman, J. R., Daluiski, A. & Einhorn, T. A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 84, A1032–A1044 (2002).
  Google Scholar
• Nemeth, E. F. et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299, 323–331 (2001).
  CAS PubMed Google Scholar
• Meunier, P. J. et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis — a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060–2066 (2002).
  CAS PubMed Google Scholar
• Reginster, J. Y. Strontium ranelate in osteoporosis. Curr. Pharm. Des. 8, 19079–1916 (2002).
  Google Scholar